How big is the Short-acting Insulin Market?

The Short-acting Insulin Market size is expected to reach USD 7.23 billion in 2024 and grow at a CAGR of 3.46% to reach USD 8.58 billion by 2029. Read More

What is the current Short-acting Insulin Market size?

In 2024, the Short-acting Insulin Market size is expected to reach USD 7.23 billion. Read More

Who are the key players in Short-acting Insulin Market?

Eli Lilly, Sanofi Aventis, Novo Nordisk AS, Pfizer and Biocon are the major companies operating in the Short-acting Insulin Market. Read More

Which is the fastest growing region in Short-acting Insulin Market?

Middle-East and Africa is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Short-acting Insulin Market?

In 2024, the North America accounts for the largest market share in Short-acting Insulin Market. Read More

What years does this Short-acting Insulin Market cover, and what was the market size in 2023?

In 2023, the Short-acting Insulin Market size was estimated at USD 6.98 billion. The report covers the Short-acting Insulin Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Short-acting Insulin Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Short-acting Insulin Companies

This report lists the top Short-acting Insulin companies based on the 2023 & 2024 market share reports. Mordor Intelligence expert advisors conducted extensive research and identified these brands to be the leaders in the Short-acting Insulin industry.